Integrating Developability Assessment into Lead Optimisation: Preclinical Aspects – Hosted by Evotec

Identifying and progressing drug candidates with the best overall drug safety profile and establishing a well-characterized translational risk profile is key in reducing clinical attrition and costs associated with the development of new drugs. To accomplish this, the ONE Evotec organization has designed a framework of activities based on a tiered approach in which in vitro assays and in vivo models are used first for compounds of interest to “flag” potential issues and identify the overall best profile, followed by confirmation of findings in more relevant, or standard regulatory, in vitro and in vivo models. The integration of this body of multi-endpoint data enables the overall risk assessment that can be used for rational decision-making.